Gilead Sciences stock gets new Livdelzi Phase 3 evidence

Published on 11/05/2026 at 16:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gilead Sciences stock is in focus after positive IDEAL results for Livdelzi in primary biliary cholangitis. Gilead plans regulatory discussions.

Livdelzi data sharpen Gilead outlook

The IDEAL study tested Livdelzi in PBC patients with moderately elevated ALP levels who received UDCA or could not tolerate it.
Gilead plans discussions with global regulatory authorities based on the results.
The Liver Meeting in Denver will feature the data alongside further liver-disease research.

Gilead Sciences, US3755581036, Illustration mit AI erstellt.

Gilead Sciences announced detailed Phase 3 IDEAL results on Thursday, November 5, 2026, adding a new clinical milestone to its liver-disease pipeline. The results were published by Business Wire ahead of their presentation at The Liver Meeting in Denver.

IDEAL expands the Livdelzi evidence base

At Week 52, 49 of 65 participants receiving Livdelzi, or 75.4 percent, achieved the composite endpoint for alkaline phosphatase normalization. The rate was 5 of 31 participants, or 16.1 percent, with placebo.

The study enrolled adults with primary biliary cholangitis whose ALP levels were above normal but below 1.67 times the upper limit of normal despite ursodeoxycholic acid treatment, or who could not tolerate that therapy. The response appeared after one month and remained sustained through Week 52.

Gilead said it will engage global regulatory authorities based on the results. That step could support future regulatory discussions, but it does not represent an approval or a filing announcement.

Denver meeting keeps liver pipeline in focus

The IDEAL findings are scheduled for presentation at The Liver Meeting, hosted by the American Association for the Study of Liver Diseases, from November 5 to 9. Gilead is also presenting long-term and real-world evidence for Livdelzi and Hepcludex in primary biliary cholangitis and chronic hepatitis delta.

Gilead Sciences stock traded at 157.27 euros on Lang & Schwarz at 16:04 CET on Thursday, November 5, 2026, 1.75 percent above the Xetra close of Wednesday, November 4.

Investors can follow the real-time quote of Gilead Sciences stock.